In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptor
- 作者：Jianbiao Zhou ; Jiaying Khng ; Viraj J. Jasinghe ; Chonglei Bi ; Chiew Hoon Serene Neo ; Mengfei Pan ; Lai Fong Poon ; Zhigang Xie ; Hanry Yu ; Allen Eng-Juh Yeoh ; Yi Lu ; Keith B. Glaser ; Daniel H. Albert ; Ste
- 关键词：Acute myeloid leukemia ; Tyrosine kinase inhibitor ; Wild-type FLT3 receptor ; Whole-body imaging technology ; In vivo
- 刊名：Leukemia Research
- 出版年：2008
- 期刊代码：186_01452126
- 类别：med
- 出版时间：July 2008
- 卷：32
- 期：7
- 页码：1091-1100
- 文件大小：1781 K
摘要
Neoangiogenesis plays an important role in leukemogenesis. We investigated the in vivo anti-leukemic effect of ABT-869 against AML with wild-type FLT3 using RFP transfected HL60 cells with in vivo imaging technology on both the subcutaneous and systemic leukemia xenograft models. ABT-869 showed a five-fold inhibition of tumor growth in comparison with vehicle control. IHC analysis revealed that ABT-869 decreased p-VEGFR1, Ki-67 labeling index, VEGF and remarkably increased apoptotic cells in the xenograft models. ABT-869 also reduced the leukemia burden and prolonged survival. Our study supports the rationale for clinically testing an anti-angiogenesis agent in AML with wild-type FLT3.